Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Profes ...